Clinical Trial Update: A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 gene therapy study (SPK-8011QQ) in adults with severe or moderately severe Hemophilia A, sponsored by Hoffmann-La Roche, is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• SPK-8011QQ

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING